A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab

ConditionsCardiovascular Diseases Atherosclerotic Cardiovascular Disease Hypercholesterolemia, Familial

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-99

SponsorNovartis Pharmaceuticals

About this trial

This study aims to evaluate the long-term adherence and persistence to inclisiran and anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) in real-world clinical practice.

Eligibility criteria

Qualifiers

A first ever prescription of injection of inclisiran, evolocumab, or alirocumab during the identification period.

Age ≥18 years at index date.

With at least 12 months data availability prior to index date.

Disqualifiers

None

Trial design

Treatments tested in this trial

Not listed

Trial groups

5,995 Participants

are grouped into 4 trial groups

Locations

This trial has no locations

Sponsors and collaborators

Novartis Pharmaceuticals

Lead sponsor

Source ClinicalTrials.gov